gms | German Medical Science

61st Annual Meeting of the German Society of Neurosurgery (DGNC) as part of the Neurowoche 2010
Joint Meeting with the Brazilian Society of Neurosurgery on the 20 September 2010

German Society of Neurosurgery (DGNC)

21 - 25 September 2010, Mannheim

Role of Arginine-Vasopressin V1a receptors for secondary brain damage following controlled cortical impact in mice

Meeting Abstract

Search Medline for

  • Raimund Trabold - Department of Neurosurgery, University of Munich Medical Center – Grosshadern, Ludwig Maximilians University, Munich, Germany
  • Katrin Rauen - Department of Neurosurgery, University of Munich Medical Center – Grosshadern, Ludwig Maximilians University, Munich, Germany
  • Nikolaus Plesnila - Royal College of Surgeons in Ireland (RCSI), Dublin, Ireland

Deutsche Gesellschaft für Neurochirurgie. 61. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC) im Rahmen der Neurowoche 2010. Mannheim, 21.-25.09.2010. Düsseldorf: German Medical Science GMS Publishing House; 2010. DocV1586

doi: 10.3205/10dgnc061, urn:nbn:de:0183-10dgnc0615

Published: September 16, 2010

© 2010 Trabold et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.



Objective: Brain edema formation and subsequent intracranial hypertension are well known to result in secondary brain damage and, hence, unfavorable outcome following traumatic brain injury (TBI). So far the knowledge on the molecular mechanisms of brain edema formation is still insufficient. Previously we showed that Arginin-Vasopressin (AVP) receptor antagonists reduce post-traumatic and post-ischemic brain edema formation. In the current study we investigated the relevance of Vasopressin V1a receptors for secondary brain damage after TBI by using V1a-receptor knock-out mice.

Methods: C57/BL6 mice and V1a-receptor knock-out mice (V1a-/-) were subjected to controlled cortical impact (CCI; 8 m/s, 1 mm). As parameters we quantified brain water content (baseline and 24 h after CCI), secondary contusion volume (15 min, 24 h and 7 d after CCI), neurological outcome (1 d before and at 7 d after CCI), body weight (in % at 7 d after CCI), and mortality.

Results: V1a-receptor deficiency significantly decreased brain water content by 29% (Mean ± SEM: 79.8%±0.3 vs. 80.6%±0.2 in controls) and secondary contusion volume by 29% (38.2±1.7 mm3 vs. 45.1±1.5 mm3 in controls) 24 h after CCI. Furthermore lack of V1a-receptor ameliorated neurological dysfunction (3.2±0.8 vs. 7.0±1.4 in controls) and reduced weight-loss (96±1.6% vs 91.0± 2.0) 7 days after CCI. All animals survived the observation period of 7 days.

Conclusions: Our data show that deficiency of V1a-receptor decreases secondary brain damage after experimental traumatic brain injury (TBI). We conclude from these findings that the V1a-receptor is a new potential drug target for the therapy of post-traumatic brain edema.